Glenmark Pharmaceuticals Ltd

ESG Factbook

Report overview

The report presents Glenmark’s FY 2024 ESG performance, including Scope 1 and Scope 2 emissions of 15,455 and 69,632 MTCO2e and Scope 3 emissions of 1,71,146 MTCO2 e. It reports a global workforce of 14,989 and describes women’s representation and other workforce measures. The company states targets including a 35% absolute Scope 1 and 2 emissions reduction by FY 2035 and carbon neutrality for Scope 1 and 2 by 2030; DNV provided limited assurance over selected disclosures.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language
Pages
File size

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Renewable energy
Water consumption
Waste
Employees
Women on the board
Workplace fatalities
Net zero target

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services